Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20398987 | 0.81 | — | — | |
| SCHEMBL15351328 | 0.81 | — | — | |
| SCHEMBL15420044 | 0.81 | MEN1 (0.31) | — | |
| SCHEMBL24424866 | 0.78 | — | — | |
| SCHEMBL24360898 | 0.76 | ALDH1A1 (0.32) | KDM4ELMNATP53HTTSMN1; SMN2 | |
| SCHEMBL15187738 | 0.75 | OPRM1 (0.32) | — | |
| SCHEMBL2236435 | 0.74 | — | — | |
| SCHEMBL1809810 | 0.74 | L3MBTL1 (0.32) | KDM4ELMNATP53HTTSMN1; SMN2 | |
| SCHEMBL13728352 | 0.74 | — | — | |
| SCHEMBL24424001 | 0.73 | KDM4E (0.30) | KDM4ELMNATP53HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| EP-4688772-A1 | BIARYL DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2026-01-15 | — | — | US | disclosed |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-114605327-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114716381-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114573510-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12220401-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| CN-114591242-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-114634447-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-9278925-B2 | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-08 | — | — | US | disclosed |
| US-9096571-B2 | Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-08-04 | — | — | US | disclosed |
| US-20140275199-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275199-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275199-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| EP-2739607-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE | Bayer Intellectual Property GmbH (DE) | 2014-06-11 | — | — | EP | disclosed |
| US-20130210811-A1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO., LTD. (KR) | 2013-08-15 | — | — | US | disclosed |
| EP-2566859-A2 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Sk Chemicals Co., Ltd. (KR) | 2013-03-13 | — | — | EP | disclosed |
| WO-2013017600-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-07 | — | — | WO | disclosed |
| WO-2011139107-A2 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | SK CHEMICALS CO.,LTD. (KR) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275199-A1 | SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE | MALT1, UGT1A3, BMI1 | KDM4E 197/4885LMNA 1389/4885TP53 139/4885 |
| US-12220401-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | KDM4E 619/4885LMNA 4225/4885TP53 899/4885 |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | POLB, POLA1, POLN | KDM4E 4229/4885LMNA 195/4885TP53 328/4885 |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | KDM4E 619/4885LMNA 4225/4885TP53 899/4885 |
| US-20130210811-A1 | PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | HSD11B1, HSD11B2, G6PC1 | KDM4E 2000/4885LMNA 744/4885TP53 3457/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | KDM4E 2304/4885LMNA 1537/4885TP53 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.